{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:44:55Z","timestamp":1794663895786,"version":"4.9.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clinre.2025.102547","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:34:12Z","timestamp":1738946052000},"page":"102547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A class of MicroRNAs as diagnostic biomarkers and therapeutic strategies in non-alcoholic fatty liver disease: A review"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2253-3361","authenticated-orcid":false,"given":"Faraz","family":"Mahdizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0800-536X","authenticated-orcid":false,"given":"Pouria","family":"Sobhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8742-3895","authenticated-orcid":false,"given":"Shokofeh","family":"Banaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.clinre.2025.102547_bib0001","first-page":"447","article-title":"Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment","volume":"111","author":"Wei\u00df","year":"2014","journal-title":"Deutsch \u00c4rztebl Int"},{"issue":"3","key":"10.1016\/j.clinre.2025.102547_bib0002","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4103\/2221-1691.338919","article-title":"Non-alcoholic fatty liver disease: epidemiology, pathophysiology and an update on the therapeutic approaches","volume":"12","author":"Abdel-Rahman","year":"2022","journal-title":"Asian Pac J Trop Biomed"},{"issue":"6","key":"10.1016\/j.clinre.2025.102547_bib0003","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/apt.17158","article-title":"The epidemiologic burden of non-alcoholic fatty liver disease across the world","volume":"56","author":"Henry","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"967","key":"10.1016\/j.clinre.2025.102547_bib0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/pgmj.2005.042200","article-title":"Treatment of non-alcoholic fatty liver disease","volume":"82","author":"Adams","year":"2006","journal-title":"Postgrad Med J"},{"issue":"4","key":"10.1016\/j.clinre.2025.102547_bib0005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102547_bib0006","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1751-2980.2008.00323.x","article-title":"Impact of non-alcoholic fatty liver disease on accelerated metabolic complications","volume":"9","author":"Fan","year":"2008","journal-title":"J Dig Dis"},{"issue":"7","key":"10.1016\/j.clinre.2025.102547_bib0007","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"36","key":"10.1016\/j.clinre.2025.102547_bib0008","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.3748\/wjg.v23.i36.6549","article-title":"Treatment options for alcoholic and non-alcoholic fatty liver disease: a review","volume":"23","author":"Singh","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102547_bib0009","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/978-3-319-48382-5_19","article-title":"Non-alcoholic fatty liver disease","author":"Engin","year":"2017","journal-title":"Obes Lipotoxicity"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","article-title":"Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH","volume":"103","author":"Pierantonelli","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.clinre.2025.102547_bib0011","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.clinre.2025.102547_bib0012","doi-asserted-by":"crossref","first-page":"293","DOI":"10.34172\/jhp.2020.37","article-title":"Protective effect of vitamin D3 and erythropoietin on renal ischemia\/reperfusion-induced liver and kidney damage in rats","volume":"9","author":"Golmohammadi","year":"2020","journal-title":"J Herbmed Pharmacol"},{"issue":"12","key":"10.1016\/j.clinre.2025.102547_bib0013","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3390\/biom10121702","article-title":"Oxidative stress in NAFLD: role of nutrients and food contaminants","volume":"10","author":"Rives","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0014","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/pr9010135","article-title":"Non-alcoholic fatty liver disease: from pathogenesis to clinical impact","volume":"9","author":"Caturano","year":"2021","journal-title":"Processes"},{"key":"10.1016\/j.clinre.2025.102547_bib0015","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate immunity and inflammation in NAFLD\/NASH","volume":"61","author":"Arrese","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.clinre.2025.102547_bib0016","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/ijms21113863","article-title":"The role of insulin resistance and diabetes in nonalcoholic fatty liver disease","volume":"21","author":"Fujii","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2025.102547_bib0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.05.001","article-title":"An overview of microRNAs","volume":"87","author":"Hammond","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.clinre.2025.102547_bib0018","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/jcp.25854","article-title":"Interplay between miRNAs and human diseases","volume":"233","author":"Paul","year":"2018","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102547_bib0019","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2174\/1566523214666141224095610","article-title":"miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir","volume":"15","author":"Thakral","year":"2015","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.clinre.2025.102547_bib0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.yjmcc.2016.03.015","article-title":"Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction)","volume":"94","author":"Chistiakov","year":"2016","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102547_bib0021","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1042\/BST0370918","article-title":"miR-21 as a key regulator of oncogenic processes","volume":"37","author":"Selcuklu","year":"2009","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"10.1016\/j.clinre.2025.102547_bib0022","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3892\/ijmm.2015.2076","article-title":"miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR","volume":"35","author":"Sun","year":"2015","journal-title":"Int J Mol Med"},{"issue":"4","key":"10.1016\/j.clinre.2025.102547_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.172","article-title":"miR-21 Ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice","volume":"8","author":"Rodrigues","year":"2017","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.clinre.2025.102547_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2021.12463","article-title":"PPAR\u03b3 attenuates hepatic inflammation and oxidative stress of non\u2011alcoholic steatohepatitis via modulating the miR\u201121\u20115p\/SFRP5 pathway","volume":"24","author":"Zhang","year":"2021","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3892\/etm.2024.12573","article-title":"Serum miR\u201129 is increased in mice with early liver fibrosis","volume":"28","author":"Matsumoto","year":"2024","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0026","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.23922","article-title":"Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis","volume":"53","author":"Roderburg","year":"2011","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.clinre.2025.102547_bib0027","doi-asserted-by":"crossref","first-page":"14564","DOI":"10.3390\/ijms241914564","article-title":"Dynamic alterations to hepatic MicroRNA-29a in response to long-term high-fat diet and EtOH feeding","volume":"24","author":"Liang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clinre.2025.102547_bib0028","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/2211536607666180531093302","article-title":"Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD)","volume":"7","author":"Jampoka","year":"2018","journal-title":"MicroRNA"},{"issue":"4","key":"10.1016\/j.clinre.2025.102547_bib0029","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/1751-2980.12716","article-title":"Circulating miR-29b positively correlates with non-alcoholic fatty liver disease in a Chinese population","volume":"20","author":"He","year":"2019","journal-title":"J Dig Dis"},{"key":"10.1016\/j.clinre.2025.102547_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/741465","article-title":"MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma","volume":"2014","author":"Gori","year":"2014","journal-title":"Biomed Res Int"},{"issue":"12","key":"10.1016\/j.clinre.2025.102547_bib0031","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3390\/biomedicines9121751","article-title":"Ability of a combined FIB4\/miRNA181a score to predict significant liver fibrosis in NAFLD patients","volume":"9","author":"Lima","year":"2021","journal-title":"Biomedicines"},{"issue":"43","key":"10.1016\/j.clinre.2025.102547_bib0032","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1093\/eurheartj\/ehw146","article-title":"Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?","volume":"37","author":"Willeit","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.clinre.2025.102547_bib0033","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/aps.2016.158","article-title":"Dicer1\/miR-29\/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis","volume":"38","author":"Liu","year":"2017","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"10.1016\/j.clinre.2025.102547_bib0034","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3390\/cells8101298","article-title":"MicroRNA-29a suppresses CD36 to ameliorate high fat diet-induced steatohepatitis and liver fibrosis in mice","volume":"8","author":"Lin","year":"2019","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.clinre.2025.102547_bib0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jhep.2012.10.024","article-title":"MicroRNA-29a-c decrease fasting blood glucose levels by negatively regulating hepatic gluconeogenesis","volume":"58","author":"Liang","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0036","article-title":"miR-29 Regulates metabolism by inhibiting JNK-1 expression in non-obese patients with type 2 diabetes mellitus and NAFLD","volume":"18","author":"Lu","year":"2023","journal-title":"Open Med (Wars)"},{"issue":"6","key":"10.1016\/j.clinre.2025.102547_bib0038","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/ijms20061499","article-title":"MicroRNA-29a disrupts DNMT3b to ameliorate diet-induced non-alcoholic steatohepatitis in mice","volume":"20","author":"Yang","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.clinre.2025.102547_bib0040","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202200348","article-title":"MicroRNA-29a compromises hepatic adiposis and gut dysbiosis in high fat diet-fed mice via downregulating inflammation","volume":"67","author":"Yang","year":"2023","journal-title":"Mol Nutr Food Res"},{"issue":"Suppl 2","key":"10.1016\/j.clinre.2025.102547_bib0041","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.orcp.2017.01.004","article-title":"Aerobic endurance training improves nonalcoholic fatty liver disease (NAFLD) features via miR-33 dependent autophagy induction in high fat diet fed mice","volume":"12","author":"Ghareghani","year":"2018","journal-title":"Obes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.clinre.2025.102547_bib0042","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1039\/D0FO02286A","article-title":"The role of microRNA-33 as a key regulator in hepatic lipogenesis signaling and a potential serological biomarker for NAFLD with excessive dietary fructose consumption in C57BL\/6N mice","volume":"12","author":"Pan","year":"2021","journal-title":"Food Funct"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0043","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/hep.26604","article-title":"Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice","volume":"59","author":"Tomita","year":"2014","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.clinre.2025.102547_bib0044","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/liv.13109","article-title":"Hepatic miR-33a\/miR-144 and their target gene ABCA1 are associated with steatohepatitis in morbidly obese subjects","volume":"36","author":"Vega-Badillo","year":"2016","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.clinre.2025.102547_bib0045","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/ijms17101620","article-title":"miR33a\/miR33b* and miR122 as possible contributors to hepatic lipid metabolism in obese women with nonalcoholic fatty liver disease","volume":"17","author":"Auguet","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.clinre.2025.102547_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224820","article-title":"Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation","volume":"14","author":"Erhartova","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.clinre.2025.102547_bib0047","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1128\/MCB.01714-12","article-title":"A regulatory role for microRNA 33* in controlling lipid metabolism gene expression","volume":"33","author":"Goedeke","year":"2013","journal-title":"Mol Cell Biol"},{"issue":"22","key":"10.1016\/j.clinre.2025.102547_bib0048","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.1073\/pnas.1102281108","article-title":"miR-33a\/b Contribute to the regulation of fatty acid metabolism and insulin signaling","volume":"108","author":"Davalos","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.clinre.2025.102547_bib0049","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/gutjnl-2018-318146","article-title":"miRNAs and NAFLD: from pathophysiology to therapy","volume":"68","author":"Gjorgjieva","year":"2019","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.clinre.2025.102547_bib0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.15171\/mejdd.2018.113","article-title":"Role of MicroRNAs in pathophysiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"10","author":"Iravani","year":"2018","journal-title":"Middle East J Dig Dis"},{"issue":"2","key":"10.1016\/j.clinre.2025.102547_bib0051","doi-asserted-by":"crossref","first-page":"123","DOI":"10.14348\/molcells.2017.2228","article-title":"IRS-2 partially compensates for the insulin signal defects in IRS-1\u2212\/\u2212 mice mediated by miR-33","volume":"40","author":"Tang","year":"2017","journal-title":"Mol Cells"},{"issue":"7369","key":"10.1016\/j.clinre.2025.102547_bib0052","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature10486","article-title":"Inhibition of miR-33a\/b in non-human primates raises plasma HDL and lowers VLDL triglycerides","volume":"478","author":"Rayner","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.clinre.2025.102547_bib0053","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1172\/JCI57275","article-title":"Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis","volume":"121","author":"Rayner","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinre.2025.102547_bib0054","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3389\/fphar.2020.00921","article-title":"Delivery of microRNA-33 antagomirs by mesoporous silica nanoparticles to ameliorate lipid metabolic disorders","volume":"11","author":"Tao","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinre.2025.102547_bib0055","article-title":"Fish oil feeding modulates the expression of hepatic MicroRNAs in a Western-style diet-induced nonalcoholic fatty liver disease rat model","volume":"2017","author":"Wang","year":"2017","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0056","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7309\/jmtm.3.1.4","article-title":"DIY-smartphone slit-lamp adaptor","volume":"3","author":"Chan","year":"2014","journal-title":"J Mob Technol Med"},{"issue":"10","key":"10.1016\/j.clinre.2025.102547_bib0057","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.495","article-title":"Alternative mechanisms of miR-34a regulation in cancer","volume":"8","author":"Slab\u00e1kov\u00e1","year":"2017","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0058","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhep.2012.08.008","article-title":"miR-34a\/SIRT1\/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease","volume":"58","author":"Castro","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102547_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2021.147182","article-title":"Cadmium chloride induces non-alcoholic fatty liver disease in rats by stimulating miR-34a\/SIRT1\/FXR\/p53 axis","volume":"784","author":"Alshehri","year":"2021","journal-title":"Sci Total Environ"},{"issue":"10","key":"10.1016\/j.clinre.2025.102547_bib0060","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2025.102547_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101244","article-title":"Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease","volume":"51","author":"Xu","year":"2021","journal-title":"Mol Metab"},{"issue":"2","key":"10.1016\/j.clinre.2025.102547_bib0062","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhep.2014.10.004","article-title":"miR-122\u2013A key factor and therapeutic target in liver disease","volume":"62","author":"Bandiera","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10020-019-0085-2","article-title":"miR-122 Promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease","volume":"25","author":"Long","year":"2019","journal-title":"Mol Med"},{"issue":"7","key":"10.1016\/j.clinre.2025.102547_bib0064","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200847","article-title":"miR-122 Inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling","volume":"13","author":"Sendi","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.clinre.2025.102547_bib0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/13813455.2019.1640744","article-title":"The miR-122 inhibition alleviates lipid accumulation and inflammation in NAFLD cell model","volume":"127","author":"Hu","year":"2021","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.clinre.2025.102547_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114420","article-title":"Prenatal dexamethasone exposure induces nonalcoholic fatty liver disease in male rat offspring via the miR-122\/YY1\/ACE2-MAS1 pathway","volume":"185","author":"Liu","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0067","article-title":"Circulating miRNAs as novel diagnostic biomarkers in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"2019","author":"Cai","year":"2019","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.clinre.2025.102547_bib0068","doi-asserted-by":"crossref","first-page":"12767","DOI":"10.3390\/ijms241612767","article-title":"MiRNA-146a\u2014A key player in immunity and diseases","volume":"24","author":"Gilyazova","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.clinre.2025.102547_bib0069","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/0008-5472.CAN-09-2792","article-title":"miR-146a Suppresses invasion of pancreatic cancer cells","volume":"70","author":"Li","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinre.2025.102547_bib0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11010-011-0727-3","article-title":"Impaired miR-146a expression links subclinical inflammation and insulin resistance in type 2 diabetes","volume":"351","author":"Balasubramanyam","year":"2011","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0071","doi-asserted-by":"crossref","first-page":"12626","DOI":"10.1038\/s41598-019-49090-4","article-title":"miR-146a Deficiency accelerates hepatic inflammation without influencing diet-induced obesity in mice","volume":"9","author":"Javidan","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.clinre.2025.102547_bib0072","first-page":"543","article-title":"miR\u2011146a Improves hepatic lipid and glucose metabolism by targeting MED1","volume":"45","author":"Li","year":"2020","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.clinre.2025.102547_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116829","article-title":"LncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p\/ROCK1 in nonalcoholic fatty liver disease","volume":"235","author":"Chen","year":"2019","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0074","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12864-018-4575-3","article-title":"A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis","volume":"19","author":"Liu","year":"2018","journal-title":"BMC Genom"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.taap.2012.04.018","article-title":"Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet","volume":"262","author":"Tryndyak","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0076","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/biom14010034","article-title":"miR-192-5p ameliorates hepatic lipid metabolism in non-alcoholic fatty liver disease by targeting Yy1","volume":"14","author":"Ma","year":"2023","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.clinre.2025.102547_bib0077","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/labinvest.2010.113","article-title":"Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice","volume":"90","author":"Pogribny","year":"2010","journal-title":"Lab Invest"},{"issue":"5","key":"10.1016\/j.clinre.2025.102547_bib0078","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","article-title":"Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis","volume":"64","author":"Pirola","year":"2015","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.clinre.2025.102547_bib0079","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105192","article-title":"A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease","volume":"9","author":"Tan","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clinre.2025.102547_bib0080","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.31050","article-title":"Lipotoxic hepatocyte-derived exosomal MicroRNA 192-5p activates macrophages through rictor\/Akt\/forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease","volume":"72","author":"Liu","year":"2020","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinre.2025.102547_bib0081","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep4.1501","article-title":"Differential associations of circulating MicroRNAs with pathogenic factors in NAFLD","volume":"4","author":"Ezaz","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clinre.2025.102547_bib0082","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.lfs.2018.07.029","article-title":"Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients","volume":"208","author":"Ye","year":"2018","journal-title":"Life Sci"},{"issue":"46","key":"10.1016\/j.clinre.2025.102547_bib0083","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.3748\/wjg.v23.i46.8140","article-title":"miR-192-5p Regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1","volume":"23","author":"Liu","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.clinre.2025.102547_bib0084","doi-asserted-by":"crossref","first-page":"e57215","DOI":"10.15252\/embr.202357215","article-title":"Dicer structure and function: conserved and evolving features","volume":"24","author":"Zapletal","year":"2023","journal-title":"EMBO Rep"},{"issue":"8\u20139","key":"10.1016\/j.clinre.2025.102547_bib0085","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/s41417-022-00432-x","article-title":"Dicer deletion in hepatocytes promotes macrophages M1 polarization through dysregulated miR-192-3p\/IGF2 in non-alcoholic steatohepatitis and hepatocellular carcinoma","volume":"29","author":"Hu","year":"2022","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"10.1016\/j.clinre.2025.102547_bib0086","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jnutbio.2014.06.012","article-title":"Interstrain differences in the progression of nonalcoholic steatohepatitis to fibrosis in mice are associated with altered hepatic iron metabolism","volume":"25","author":"Shpyleva","year":"2014","journal-title":"J Nutr Biochem"},{"issue":"4","key":"10.1016\/j.clinre.2025.102547_bib0087","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.30645","article-title":"MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes","volume":"70","author":"He","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.clinre.2025.102547_bib0088","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.aohep.2019.12.003","article-title":"Identification and study of differentially expressed miRNAs in aged NAFLD rats based on high-throughput sequencing","volume":"19","author":"Zhang","year":"2020","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102547_bib0089","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141513","article-title":"Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis","volume":"131","author":"He","year":"2021","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0090","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1017\/S095442242100038X","article-title":"NAFLD and vitamin D: evidence for intersection of microRNA-regulated pathways","volume":"36","author":"Zhang","year":"2023","journal-title":"Nutr Res Rev"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0091","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2209335","article-title":"Relevance of vitamin D on NAFLD and liver fibrosis detected by vibration controlled transient elastography in US adults: a cross-sectional analysis of NHANES 2017-2018","volume":"55","author":"Ji","year":"2023","journal-title":"Ann Med"},{"issue":"11","key":"10.1016\/j.clinre.2025.102547_bib0092","doi-asserted-by":"crossref","first-page":"9631","DOI":"10.3390\/ijms24119631","article-title":"Extracellular vesicles as markers of liver function: optimized workflow for biomarker identification in liver disease","volume":"24","author":"Paluschinski","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"40","key":"10.1016\/j.clinre.2025.102547_bib0093","doi-asserted-by":"crossref","first-page":"14518","DOI":"10.1073\/pnas.1215767111","article-title":"MicroRNA-223 coordinates cholesterol homeostasis","volume":"111","author":"Vickers","year":"2014","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.clinre.2025.102547_bib0094","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41574-022-00675-6","article-title":"Macrophage functional diversity in NAFLD - more than inflammation","volume":"18","author":"Barreby","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102547_bib0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.31805","article-title":"Exosomes and MicroRNA-223 at the intersection of inflammation and fibrosis in NAFLD","volume":"74","author":"Szabo","year":"2021","journal-title":"Hepatology"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T02:17:10Z","timestamp":1744510630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125000270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2210740125000270"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102547","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A class of MicroRNAs as diagnostic biomarkers and therapeutic strategies in non-alcoholic fatty liver disease: A review","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102547","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102547"}}